{
  "doc_id": "dlcg_pal_onkogen_dreven_nsclc_v.1_admgodk_010724",
  "created_date": "2024",
  "country": "DK",
  "source_type": "clinical_guideline",
  "chunks": [
    {
      "heading": "",
      "text": "nd nd n-d",
      "start_page": 1,
      "end_page": 1
    },
    {
      "heading": "Version 1.0",
      "text": "2024 2024 (DLCG) July July 2024",
      "start_page": 1,
      "end_page": 1
    },
    {
      "heading": "AUDIT",
      "text": "1, 1, 2025",
      "start_page": 1,
      "end_page": 1
    },
    {
      "heading": "INDECTION",
      "text": "Clinical Clinical FtRange) Guidance Guidance •Requirements",
      "start_page": 1,
      "end_page": 2
    },
    {
      "heading": "Contents",
      "text": "HARBAND'COURSE COURSE .......................................................onkogen-Driving onkogen-Driving ......................................................................................... 3. Basis ......................................................................6. Monitoring ..................................References References ....................................5 Method .................................6.Monitoring ......................................... Annex 3 - DK. DK.................. 7. Annex: 8. 8. ................ Annex 1 • __MEDTERM25_ __MEDTERM25_ (A) korotherapy korotherapy +/- guidelines guidelines (A), chemotherapy chemotherapy + /-__medterm46__-guidments __medterm46__-guidments (A); komatherapy komatherapy +/drive__MEDERTM49___MEDERM25_en drive__MEDERTM49___MEDERM25_en (A). (departmental departmental management/committee committee (B) base_MEDTERM25__emotetherapy base_MEDTERM25__emotetherapy +/- 2 2 (3). __midterm20__ __midterm20__ (B/C) status status .platinumbase__MEDERM25___enterM25_imotherapy platinumbase__MEDERM25___enterM25_imotherapy (where applicable) 2 2 (3). medicine medicine (ATHERM23_FORT)",
      "start_page": 2,
      "end_page": 5
    },
    {
      "heading": "2. Introduction",
      "text": "of of patients' tumors and/blood blood (ctDNA). sequence sequence (NGS). bugs bugs (variants); versus versus __MEDTERM2_exonsertion). the the genes: EGFR_, KRAS (G12C), BRAF (V600E), back back (__metherM0__ __metherM0__ variant) erythropoietins. erythropoietins.",
      "start_page": 6,
      "end_page": 7
    },
    {
      "heading": "3. Basis",
      "text": "board board (if available) TKI TKI \"beyond progression\" option. option. 3) patients patients (residual residual life) sequence sequence (\"loss\" oncogenic oncogenic driver/histological transformation and/resistance resistance variants). 4) for for non-88__ 88__ - Selected patients (like few) primary primary tumor/DNA DNA (ctDNA) bloodstream bloodstream (shedding tumor), by by ct=be be found: account account (negative negative results), and and __MIDTERM137___mergers/mutations [1a]. evidence evidence [1b] (___MEDERTM2__, ___MEDERTM2__, __medTERM143____), [1c] (NTRAK 1/2/3, [2a] (__MEDterm141__ amplification) and [2b] [BRAF BRAF non-V600E) (1). The placebo/MEDTERM4___= subgroups subgroups (status status (5)[1b], CNS CNS metastases). of of ≥ events events (42% versus 47%), compared to __medterm10_/time time (5 5 months). arms arms (3-4%). following following categories: 5,8 %, rash 0% 6, 6,%. of of ≥ events events (13% vs 8%)) for patients ≥ PS PS ≥ reactions reactions (13) [5]. __ __ MEDTERM46_/rash rash (14.6%), diare (5.4%) and stomatitis/mucositis (5.4%). TKIS TKIS (17-19) [1b]. A metaanalysis (20) [1a] nausea nausea (15.8 % 7 7 % with __MEDTER77_______===+++== ORR ORR 82% versus versus 23% was was 64% for ~MEDTERM69__ and 19% for }one one (1 %) 25 25 (23%) with with __MEDARM69_- 82. 82.4% (13.9% grade 3), hypergliceridemia 60.7% (13.2% grade3), oedema 51.2% (2.4% grade 3) 7 7 % (2.4% degree 3) 23. 23.1% (1.7% grade 3) [27][1b]. cholesterol cholesterol and/or or CYP_MED",
      "start_page": 8,
      "end_page": 14
    },
    {
      "heading": "__MEDTERM0_VERSUS __MIDTERM1_VERSUS _MEDTERM2___",
      "text": "for for __midterm6_91% versus 68% for ~medterm5___ (23)[1b]. 10 10 % partner partner (PLEKHH2, PLEKHH2, KANK1), alectinib alectinib (28-30)[4]. In addition, patients' a a day; with with EML^__midterm11_ __midterm11_ (31) [2b] longer longer __medterm2_m= studies studies (34)[2b]. __medterm88__ was 77% gain gain (8%) and neutropenia (4%). had had 36% diagnosis diagnosis (35}. doubling doubling (2 2 months) chemotherapy chemotherapy +/- _RET-translocated ______ (38) __MIDTERM97__ __MIDTERM97__ (38). doubling doubling (2 2 months) based based chemotherapy+/-is is 84% versus chemotherapy, 65%. Patients with risk/risk profile: drivers drivers (13)[5]. chemotherapy chemotherapy +/ guidelines guidelines (B) line line (cohorte C) lines lines (coorte B). PHAROS PHAROS (42)[2b]. chemotherapy chemotherapy plus/included. included.",
      "start_page": 15,
      "end_page": 18
    },
    {
      "heading": "Ad. Recommendation 7",
      "text": "a a •MEDTERM229__- a a ~response response (44)[2b]. not not head-patients patients (44)[IMMUNOTARGET IMMUNOTARGET (39)[2b] study study (50) [1b] and and KRA'type. type. Immunet: were were 26% months months m_medterm230__$months months (HER2) /NSCLC_. NSCLC_., for for non-medesterm125__/ recommended recommended (69). histology histology (planocellullearous planocellullearous carcinoma) re-biopsy re-biopsy (progressive progressive metastases) histologi histologi (_MEDERT275__ or planofelullearms). PFS_ PFS_ (6,3/2 2 months) and CNS_MEDTERM229____ (12,8/3 3 months). to to chemotherapy: SAE (all) 32-52% vs 20%. Adverse events ≥ 3: 72-92% vs 48%. __medterm47__-arms __medterm47__-arms 10%-22% vs 5%. in in 10-22% vs 4% therapy therapy __MEDERTM47__/or or _25% MEDTERM157_FREE) marrow marrow impact: 71% (co-arm) vs 24% (___MEDTERM7_arm). arms arms (3-4%). 2022 2022 (2) [5] combination combination Osimertinib+ on on 11/150 150 (77) [1b] 3-arm 3-arm study: chemotherapy chemotherapy (BP). patients patients (previously previously __MIDTERM107__TKI) __midterm81___ __midterm81___ + platinum-duplicate (AP) versus __MTERTM84__+ platinum-diublet (BP) in in __ENTERTEM79__~ chemotherapy chemotherapy [ABP) versus versus (AP), 9 9 (even even work). study study (86) [2b], PD-L1 PD-L1 ≥ 1% (≥ 50 % in 74% of patients). study study (87) simultaneously simultaneously (compound mutations) development development (_alectinib _alectinib (2. generation TKI). progression progression (generation generation TKI) with with ~0-1 0-1 (2) _MEDERM106__ _MEDERM106__ (A) recommendation recommendation 14",
      "start_page": 18,
      "end_page": 28
    },
    {
      "heading": "SELPERCATINIB",
      "text": "ORR_of ORR_of 64% against against platinum- based chemotherapy +/- __midTERM146__ __midTERM146__ (38)[1b]. shows shows ___MEDARM147__: platinum-driven platinum-driven chemotherapy+/-__MEDTERMEM10__.__MEDERM144___:84% (_MEDhem_MEDERM8_FOR_WITH_EXTATE_HOUSE). drivers drivers (13)[5]. Medical Medical Council'status status 0-2(3) immunotherapy immunotherapy (where applicable) 2. 2. (3.) drivers drivers (13)[5]. chemotherapy chemotherapy +/- 2. 2. (3.) __withtermM37_ __withtermM37_ (B /C) to to platinum- based chemotherapy+/ immunotherapy (13). ORR_50. ORR_50.7% - 62.1% __MIDTERM144-_43. __MIDTERM144-_43.4%- 47% intracranial intracranial activity: __midterm144__ >50%. (47, 101)[2b]. __ENTERTEM144-__ __ENTERTEM144-__ 32%, ~months months (102)[2 b]. STUDY STUDY (_MEDERM40___) 8 8 % of patients, -common common (of of patients). investigate investigate OSMULTUR_MED/MED/ MEDATER_MEDS/ diarrhoea diarrhoea (12%), ALT increase (8%) increase increase (5%) vs neutropenia (12%), fatigue (6%) neutropenic neutropenic (5%) included included (107)[2b]. 42. 42.9% months months _medterm147_% A763_Y764insx A763_Y764insx (4-6% ins ins variants) __midterm54___ __midterm54___ (58, 59) [4]. neutropenia neutropenia (33%) and rash 11%. study study (110)[2b] 54__ 54__ (160 mg) 2- ins ins (p. p.(A763-L777)). limited limited efficacy: __medterm144__ 28%, dose dose ~MEDTERM5___. ERBB2(HER2) treatment treatment options: responses responses (plus plus SD>16 weeks) of 11%. study study (112)[2b] blockade blockade + level level (2.4 mg/kg); ORR 49% developed developed ≥ 38. 38.6%. 12. 12.9% of patients (≥ HER2 HER2 overexpression; __MIDTERM144-_24.5% mr___MEDERTM72___emtansine mr___MEDERTM72___emtansine (T-DM1) study study (changes changes (35,2%), diarrhoea (31,1%), fatigue (27,5%) gain gain _2MMED_MED_MID_MEDS_MED) 22 22 NSCLCDURING) had 22 •2022 2022 (61)[2a]. 59. 59.1% at at baseline; ___MEDERTM144____ were 64% with __medTERM145__page===in in patients' Rationale Rationale Recommendations: \"guidelines. guidelines. \"Consider\": guide guide (see Annex 2) treating treating doctor/ ensure ensure one'regions. regions.",
      "start_page": 28,
      "end_page": 36
    },
    {
      "heading": "4. References",
      "text": "with Alectinib: Oncologist. Oncologist. 2020;25(4):Res. Res. 2023;29(18):3579-91.",
      "start_page": 39,
      "end_page": 41
    },
    {
      "heading": "5. Method",
      "text": "on on abstract- order order • Øllegaard Øllegaard (of of interest), Gødstrup Gødstrup • Urbanska Urbanska (of of interest); oncologi; Rigshospitalet Rigshospitalet • Line Brøndum (of of interest) Gådstrrup Gådstrrup • Sundbye Sundbye (of of interests), Danish Danish Agency'cooperation cooperation relations: companies/lists-over-related companies/members. members.",
      "start_page": 45,
      "end_page": 46
    },
    {
      "heading": "6. Monitoring",
      "text": "Register Register (DLCR) Programme Programme (RKKP), guidelines guidelines (the the BEK).",
      "start_page": 47,
      "end_page": 47
    },
    {
      "heading": "Annex 1 • Search strategy",
      "text": "Title (on guideline) (NSCLC NSCLC )",
      "start_page": 48,
      "end_page": 48
    },
    {
      "heading": "DMCG",
      "text": "Guideline Guideline Secretariat",
      "start_page": 48,
      "end_page": 48
    },
    {
      "heading": "Last Completed",
      "text": "NSCLC NSCLC ^generation generation TKI; date date (period): and and Language: Publication Publication type: inserted. inserted. Non-respond respond __FORMEDERTS",
      "start_page": 48,
      "end_page": 49
    },
    {
      "heading": "Search Strategies (Copied In)",
      "text": "Medline Medline (number of hits=78) found found #78 78 #212 212 #184 184 #88 88 #Lent Lent On: 23 23 04:50:11 2023 Search: ((((OR OR _ALK_) AND ((observatory[Filter] OR randomizedcontrolal[Filder] AND (2010/1/1/3000/12MED",
      "start_page": 49,
      "end_page": 50
    },
    {
      "heading": "DMCG",
      "text": "Contact with me",
      "start_page": 50,
      "end_page": 50
    },
    {
      "heading": "Last Completed",
      "text": "inje inje ^Required line) Audience Audience Language: OR OR Non-gslinserk____MEDERTM22_RATEM22 gslinserk____MEDERTM22_RATEM22 ♪ ♪ I'it it ♪ goodness. goodness. ♪ Happy birthday ♪",
      "start_page": 50,
      "end_page": 51
    },
    {
      "heading": "DOLG",
      "text": "with with me",
      "start_page": 52,
      "end_page": 52
    },
    {
      "heading": "Last Completed",
      "text": "Background Inclusion/for for 'Comparison inje",
      "start_page": 52,
      "end_page": 53
    },
    {
      "heading": "Search Strategies (Copied In)",
      "text": "Publisher_gl_Gl*Gl(gl=OR59) Query Query #59 59 #212 212 #306 306 #638 638 #Information Information (NCBI) Medicine Medicine (NLM). Sent Sent On: 23 23 05:22:37 2023 Search: ((((OR OR Non-OR OR __MEDERTEM6_OR",
      "start_page": 53,
      "end_page": 53
    },
    {
      "heading": "DMCG",
      "text": "Clinical Clinical Directions",
      "start_page": 53,
      "end_page": 54
    },
    {
      "heading": "Last Completed",
      "text": "__MEDTERM_OREM __MEDTERM_OREM OR_ORS) OTHERS OTHERS ♪ Databases Databases (Strategies Strategies (for for 'inje inje .public public Language: or or Non-or or OM-cancer cancer - Sung Sung cancer",
      "start_page": 54,
      "end_page": 55
    },
    {
      "heading": "PubMed (number of hits=129)",
      "text": "•Query Query #129 129 #212 212 #371 371 #716 716 #Lent Lent On: 23 23 04:14:35 2023 Search: ((((cancer cancer [Filter]) AND (2010/1/1/3000/12[pdat]) AND (english[Filters])",
      "start_page": 55,
      "end_page": 55
    },
    {
      "heading": "Annex 2 - Abbreviations and explanations",
      "text": "treatment treatment (effect data / options options / treatment treatment / of of efficacy/treatment treatment difficult). guideline guideline / 5. 5.",
      "start_page": 56,
      "end_page": 58
    },
    {
      "heading": "for for NPP/PAA/EAP",
      "text": "Denmark Denmark (in in ProMedicin) medicine medicine (e.g. repotrectinib) in so-called \"programs programs (NPP) / \"early-access programs\" (EAP) / Pre-Approval Access (PAA). country country (of of EMA). the the patient'the the study's in- programs programs (PAAs). patient patient (by by patient) the the company'procedures procedures (the the medicine) medications. medications.",
      "start_page": 58,
      "end_page": 59
    },
    {
      "heading": "clinical clinical guideline",
      "text": "Groups Groups (DMCG.dk) Programme Programme (RKP). found found at:Health Health Authority'packages packages • content content • disease disease area: Service Service (Kreftplan IV) and RKPP.",
      "start_page": 60,
      "end_page": 60
    },
    {
      "heading": "heading heading <5. Method> (from previous page)",
      "text": "Row 1: Row Row 2: group. group.",
      "start_page": 46,
      "end_page": 46
    },
    {
      "heading": "heading heading <Last completed>",
      "text": "Row 1: Title (on guideline)(__MIDTERM1___ __MIDTERM1___ ) Row 2: DMCG·DOLG Row 3: method method specialist•Row Row 4: Last completed",
      "start_page": 48,
      "end_page": 48
    },
    {
      "heading": "heading heading <Last completed>",
      "text": "Row 1: the the subject: Row 2: Background•generation generation TKI; Row Row 3: exclusion exclusion criteria· publication publication (period): date date Language: English Publication type: of of interest",
      "start_page": 48,
      "end_page": 48
    },
    {
      "heading": "heading heading <Last completed>",
      "text": "Row-Row Row 4:",
      "start_page": 48,
      "end_page": 48
    },
    {
      "heading": "heading heading <Last completed>",
      "text": "Row 1: Row 2: Alectinib Row 3: Brigatinib Row 4: __MIDTERM2__ Row 5: __medTERM3__ Row 6: ~MEDTERM4__ Row 7: Row 8:",
      "start_page": 48,
      "end_page": 48
    },
    {
      "heading": "heading heading <Last completed>",
      "text": "Row 1: Row Row 2: rate Row 3: Output Row 4: Row Row 5: response Row 6: Row Row 7: Row Row 8: survival Row 9: Row Row 10: Row Row 11: Row Row 12: events",
      "start_page": 48,
      "end_page": 48
    },
    {
      "heading": "heading heading <Last completed> (column 1)",
      "text": "Row 1: Title (on guideline) Row 2: DMCG Row 3: Row Row 4: Last completed",
      "start_page": 48,
      "end_page": 48
    },
    {
      "heading": "heading heading <Last completed> (column 1)",
      "text": "Row 1: Background Row 2: exclusion exclusion criteria",
      "start_page": 48,
      "end_page": 48
    },
    {
      "heading": "heading heading <Last completed> (column 1)",
      "text": "Row-Row-Shop-Row Row 2: •Row Row 3: Lung Lung cancer~Care Care __medterm3__^Platinom-based ►Row Row 4:",
      "start_page": 48,
      "end_page": 48
    },
    {
      "heading": "heading heading <Last completed> (column 2)",
      "text": "Row 1: Row 2: Row 3: Row 4: Row 5: Row 6: Row 7: Row 8: Row 9: Row 10: Row 11: Row 12:",
      "start_page": 48,
      "end_page": 48
    },
    {
      "heading": "heading heading <Search strategies (copyed in)>",
      "text": "Row 1:",
      "start_page": 49,
      "end_page": 49
    },
    {
      "heading": "heading heading <Search strategies (copyed in)>",
      "text": "Row 1: Databases (primary literature)• search search (dd/mm/yyyy)• search search (name(e))) Row 2: PubMed",
      "start_page": 49,
      "end_page": 49
    },
    {
      "heading": "heading heading <Search strategies (copyed in)>",
      "text": "Row 1: Search--Add to builder--Query--Row Row 2: #5·Add...78 Row 3: #4 • Add...Row Row 4: #3 • Ad...Row Row 5: #2 •add..88 Row 6: #1 • add..85.257",
      "start_page": 49,
      "end_page": 49
    },
    {
      "heading": "heading heading <Last completed>",
      "text": "Row 1: Title (on guideline) •NSCLCRow NSCLCRow 2: DMCG^DOLG Row 3: metsspecialist metsspecialist •Rightinglinesecretariat Row 4: Last completed •",
      "start_page": 50,
      "end_page": 50
    },
    {
      "heading": "heading heading <Last completed>",
      "text": "Row 1: subject subject • Row 2: Background • NSCLC NSCLC • generation generation TKI; Row Row 3: criteria criteria • publication publication (period): date date Language: English Publication type: including including RCTs",
      "start_page": 50,
      "end_page": 50
    },
    {
      "heading": "heading heading <Last completed>",
      "text": "Row Row 2: Row Row 3: inserted. inserted.•funded-based funded-based Or/Row Row 4:",
      "start_page": 50,
      "end_page": 50
    },
    {
      "heading": "heading heading <Last completed>",
      "text": "Row 1: Row Row 2: Row Row 3: Row Row 4: Row Row 5: Row Row 6: Row Row 7: OR Row 8: Row Row 9: Row Row 10: Row Row 11: OR Raw 12: Row Row 13: Row Row 14: events",
      "start_page": 50,
      "end_page": 50
    },
    {
      "heading": "heading heading <Last completed> (column 2)",
      "text": "Row 1: Population2°Population2 Row 2: •Row Row 3: •ROW ROW 4: ▪Lung Row 5: ^Row Row 6: •Non-Row Row 7:",
      "start_page": 50,
      "end_page": 50
    },
    {
      "heading": "heading heading <Last completed> (column 3)",
      "text": "OURow OURow 2: continuesRow: ~Or Or •Row Row 4: Prop Prop 5:",
      "start_page": 50,
      "end_page": 50
    },
    {
      "heading": "heading heading <Last completed> (column 4)",
      "text": "Row 1: e Row 2: Row 3: Row 4: Row 5: Row 6: Row 7: Row 8: e Row 9: Row 10: Row 11: Row 12: Row 13: e Raw 14:",
      "start_page": 50,
      "end_page": 50
    },
    {
      "heading": "heading heading <DOLG>",
      "text": "Row 1: Databases (primary literature)• search search (dd/mm/yyyy)• search search (name(e))) Row 2: PubMed",
      "start_page": 51,
      "end_page": 51
    },
    {
      "heading": "heading heading <DOLG>",
      "text": "Row 1: Search--Add to--Query--Row Row 2:--builder--Row 3:-- 5Add.--794-- Row 4:--- 4Add,-- 298,212-- -- Row 5:-- 3Add--147.148--",
      "start_page": 51,
      "end_page": 51
    },
    {
      "heading": "heading heading <DOLG>",
      "text": "Row 1: Title (on guideline) •NSCLCRow NSCLCRow 2: DMCG^DOLG",
      "start_page": 51,
      "end_page": 51
    },
    {
      "heading": "heading heading <Last completed>",
      "text": "Row 1: specialist specialist • Row Row 2: Last completed",
      "start_page": 52,
      "end_page": 52
    },
    {
      "heading": "heading heading <Last completed>",
      "text": "Row 1: the the subject: Row 2: Background•generation generation TKI; Row Row 3: exclusion exclusion criteria· publication publication (period): date date Language: English Publication type: of of interest",
      "start_page": 52,
      "end_page": 52
    },
    {
      "heading": "heading heading <Last completed>",
      "text": "of of 1: PresidentPopulationen3 PresidentPopulationen3 •Intervention1^Row Row 2: courice1 ceRow 3: inserted. inserted. •Row Row 4:",
      "start_page": 52,
      "end_page": 52
    },
    {
      "heading": "heading heading <Last completed>",
      "text": "Row 1: Row 2: Selpercatinib Row 3: OR Row 4: Pralsetinib Row 5: OR Row 6: Checkpoint- Row 7: Row Row 8: Pembrolizum Row 9: Row Row 10: __MIDTERM2__ Row 11: Row 12: Row 13: Row 14: Row 15:",
      "start_page": 52,
      "end_page": 52
    },
    {
      "heading": "heading heading <Last completed>",
      "text": "Row 1: Row Row 2: Row Row 3: Row Row 4: Row Row 5: Row Row 6: Row Row 7: OR Row 8: Row Row 9: Row Row 10: Row Row 11: OR Raw 12: Row Row 13: Row Row 14: events",
      "start_page": 52,
      "end_page": 52
    },
    {
      "heading": "heading heading <Last completed> (column 2)",
      "text": "Row 1: Population3°Population3 Row 2: •Row Row 3: •ROW ROW 4: • Row Row 5: •OR Row 6: ▪ Non-Row Row 7:",
      "start_page": 52,
      "end_page": 52
    },
    {
      "heading": "heading heading <Last completed> (column 3)",
      "text": "Square Square Row: •Row Row © Row +Row Outcomes1 •Outcomes1 Row 2: courover1 ceRow 1: ~Platform-based Platform-based Platform-Row Row 4:",
      "start_page": 52,
      "end_page": 52
    },
    {
      "heading": "heading heading <Last completed> (column 4)",
      "text": "Row 1: Row 2: Row 3: Row 4: Row 5: Row 6: Row 7: Row 8: Row 9: Row 10: Row 11: Row 12: Row 13: Row 14:",
      "start_page": 52,
      "end_page": 52
    },
    {
      "heading": "heading heading <DMCG>",
      "text": "Row 1: Databases (primary literature)• search search (dd/mm/yyyy)• search search (name(e))) Row 2: PubMed",
      "start_page": 53,
      "end_page": 53
    },
    {
      "heading": "heading heading <DMCG>",
      "text": "Row 1: Search--Add to builder--Query--Items found-- -- Row 2:--- 5:-Addd.--59-- Row 3:-- 4:-- Add--298,212--Row 4:--",
      "start_page": 53,
      "end_page": 53
    },
    {
      "heading": "heading heading <DMCG>",
      "text": "Row 1: Title (on guideline) •NSCLCRow NSCLCRow 2: DMCG^DOLG Row 3: metsspecialist metsspecialist •Recommendation linesecretariat",
      "start_page": 53,
      "end_page": 53
    },
    {
      "heading": "heading heading <Last completed>",
      "text": "Row 1: Last completed",
      "start_page": 54,
      "end_page": 54
    },
    {
      "heading": "heading heading <Last completed>",
      "text": "Row 1: the the subject: Row 2: Background•generation generation TKI; Row Row 3: exclusion exclusion criteria· publication publication (period): date date Language: English Publication type: of of interest",
      "start_page": 54,
      "end_page": 54
    },
    {
      "heading": "heading heading <Last completed>",
      "text": "right right right- Row Row 2: •intervention1ow right 3: inserted. inserted.",
      "start_page": 54,
      "end_page": 54
    },
    {
      "heading": "heading heading <Last completed>",
      "text": "Row 1: Row 2: EntrectinibRow 3: OR Row 4: Row Row 5: __MIDTERM2___ Row 6: OR Row 7: ~MEDTERM3___OR Row 8: }MEDTERM4_OR Row 9: Checkpoint- Row 10: Row Row 11: Pembrollizum Row 12: Row Row 13: •MEDTERM5__row 14: Row 15: Row 16:",
      "start_page": 54,
      "end_page": 54
    },
    {
      "heading": "heading heading <Last completed>",
      "text": "Row 1: Row Row 2: Row Row 3: Row Row 4: Row Row 5: Row Row 6: Row Row 7: OR Row 8: Row Row 9: Row Row 10: Row Row 11: OR Raw 12: Row Row 13: Row Row 14: events",
      "start_page": 54,
      "end_page": 54
    },
    {
      "heading": "heading heading <Last completed>",
      "text": "Row 1: Databases (primary literature)• search search (dd/mm/yyyy)• search search (name(e))) Row 2: PubMed",
      "start_page": 54,
      "end_page": 54
    },
    {
      "heading": "heading heading <Last completed> (column 2)",
      "text": "Row 1: Population4°Population4 Row 2: •Row Row 3: •ROW ROW 4: • Row Row 5: •OR Row 6: ▪ Non-Row Row 7:",
      "start_page": 54,
      "end_page": 54
    },
    {
      "heading": "heading heading <Last completed> (column 3)",
      "text": "Rowway 1: Row Row 2: •Row Row 3: ~MedTERM4_OR MedTERM4_OR Checkpoint- across across events:Row Row 4:",
      "start_page": 54,
      "end_page": 54
    },
    {
      "heading": "heading heading <Last completed> (column 3)",
      "text": "Row 1: search search (dd/mm/yyyy) Row 2: 23.11.2023",
      "start_page": 54,
      "end_page": 54
    },
    {
      "heading": "heading heading <Last completed> (column 4)",
      "text": "Row 1: Row 2: Row 3: Row 4: Row 5: Row 6: Row 7: Row 8: Row 9: Row 10: Row 11: Row 12: Row 13: Row 14:",
      "start_page": 54,
      "end_page": 54
    },
    {
      "heading": "heading heading <PubMed (number of hits=129)>",
      "text": "Row 1: Search--Add to builder--Query--Items found-- -- Row 2: #5-- Add---129-- Row 3: #4--add--298,212--Row 4: #3-- Add--3.371--Row 5: #2-- Ad---\"716-- \" Row 6: #1-\"Add--\"85,082·",
      "start_page": 55,
      "end_page": 55
    }
  ]
}